Citius Pharmaceuticals closes $5 million registered direct offering

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) completed a registered direct offering that raised approximately $5 million in gross proceeds, the company announced.

The biopharmaceutical company sold 5,076,143 shares of common stock at $0.985 per share under the offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Citius issued warrants to purchase up to 5,076,143 additional shares at an exercise price of $0.86 per share.

The warrants are exercisable immediately and will expire five years following the effective date of a registration statement for the underlying shares. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.

Citius stated it plans to use the net proceeds to support the commercial launch of LYMPHIR, including milestone and regulatory payments, development initiatives for product candidates, and general corporate purposes.

The common stock portion of the offering was conducted under a shelf registration statement filed with the Securities and Exchange Commission in February 2024 and declared effective in March 2024. The warrants were issued through a private placement under securities law exemptions.

Citius develops critical care pharmaceutical products and owns approximately 71% of Citius Oncology, which launched LYMPHIR in December 2025 as a targeted immunotherapy for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma.

You May Also Be Interested In

• Ambiq launches public offering of 1.8 million shares
• QXO faces stockholder lawsuit ahead of TopBuild merger vote
• Definium's LSD-based pill meets Phase 3 endpoints for depression